NeoGenomics Quarterly Cash Flow Statement
NASDAQ: NEOHealth CarePrecision InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NeoGenomics free cash flow
In the quarter ended Jun 30, 2026, NeoGenomics generated $20.0 million of operating cash flow and spent $8.2 million on capital expenditures. That left free cash flow of $11.7 million, a free-cash-flow margin of 5.8% of revenue. Free cash flow was down 16.2% from the prior year's $14.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
NeoGenomics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 2.24M | -17.11M | -9.88M | -27.13M | -45.09M | -25.92M | -15.32M | -17.70M | -18.64M | -27.06M | -14.33M | -18.52M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 8.58M | 8.78M | 8.76M | 8.80M | 9.14M | 9.37M | 9.83M | 9.62M | 9.75M | 9.90M | 9.58M | 9.35M |
| Stock-Based Compensation | 8.22M | 9.64M | 8.04M | 10.31M | 12.21M | 10.75M | 8.33M | 0 | 8.84M | 7.77M | 6.99M | 0 |
| Change in Working Capital | 8.95M | -17.85M | -5.13M | 5.52M | 7.53M | -29.75M | 3.25M | -6.33M | 9.26M | -25.74M | 8.76M | -7.22M |
| Operating Cash Flow | 19.96M | -8.14M | 1.34M | 8.88M | 20.33M | -25.33M | 9.80M | 9.25M | 13.89M | -25.91M | 17.78M | -5.50M |
| Capital Expenditures | -8.22M | -5.00M | -7.87M | -8.31M | -6.32M | -4.50M | -11.60M | -10.80M | -13.08M | -5.58M | -7.06M | -4.27M |
| Investing Cash Flow | -8.32M | -5.00M | -6.30M | -277.00K | -9.31M | 3.56M | -5.47M | -3.52M | 7.31M | 14.53M | 17.20M | 20.82M |
| Financing Cash Flow | -12.24M | -338.00K | 431.00K | 765.00K | -202.43M | 949.00K | 687.00K | 1.18M | 1.97M | 816.00K | 1.27M | 1.84M |
| Net Change in Cash | -604.00K | -13.47M | -4.53M | 9.39M | -191.42M | -20.82M | 5.02M | 6.91M | 23.17M | -10.57M | — | 17.16M |
| Free Cash Flow | 11.74M | -13.14M | -6.53M | 570.00K | 14.01M | -29.83M | -1.80M | -1.55M | 814.00K | -31.50M | 10.73M | -9.77M |
This table shows 12 quarterly periods of NeoGenomics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NEO's reporting calendar. What is a cash flow statement?